Benefits of combination of insulin degludec and liraglutide are independent of baseline glycated haemoglobin level and duration of type 2 diabetes

Diabetes, Obesity & Metabolism
Helena W RodbardS C L Gough

Abstract

To evaluate, using post hoc analyses, whether the novel combination of a basal insulin, insulin degludec, and a glucagon-like peptide-1 receptor agonist, liraglutide (IDegLira), was consistently effective in patients with type 2 diabetes (T2D), regardless of the stage of T2D progression. Using data from the DUAL I extension [insulin-naïve patients uncontrolled on oral antidiabetic drugs (OADs), n = 1660, 52 weeks] and DUAL II (patients uncontrolled on basal insulin plus OADs, n = 398, 26 weeks) randomized trials, the efficacy of IDegLira was investigated with regard to measures of disease progression stage including baseline glycated haemoglobin (HbA1c), disease duration and previous insulin dose. Across four categories of baseline HbA1c (≤7.5-9.0%), HbA1c reductions were significantly greater with IDegLira (1.1-2.5%) compared with IDeg or liraglutide alone in DUAL I. In DUAL II, HbA1c reductions were significantly greater with IDegLira (0.9-2.5%) than with IDeg in all but the lowest HbA1c category. In DUAL I, insulin dose and hypoglycaemia rate were lower across all baseline HbA1c categories for IDegLira versus IDeg, while hypoglycaemia was higher with IDegLira than liraglutide, irrespective of baseline HbA1c. In DUAL II, insu...Continue Reading

References

Jan 17, 2012·Diabetes Research and Clinical Practice·Bruce Bode
Feb 9, 2012·Diabetic Medicine : a Journal of the British Diabetic Association·M PeyrotP-M Schumm-Draeger
Sep 4, 2012·Current Medical Research and Opinion·Ning WuKelly Wilkey
Aug 2, 2014·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Jiten VoraSteve C Bain
Aug 13, 2014·Diabetes Care·John B BuseUNKNOWN NN9068-3912 (DUAL-II) Trial Investigators

❮ Previous
Next ❯

Citations

Jun 24, 2016·Expert Review of Endocrinology & Metabolism·Stephen Cl GoughVincent C Woo
Aug 4, 2016·Expert Opinion on Biological Therapy·K StinkensC Mathieu
Jul 29, 2016·Expert Opinion on Drug Metabolism & Toxicology·Elizabeth Mary Lamos, Stephen N Davis
Mar 30, 2017·Expert Review of Clinical Pharmacology·Lauge ØstergaardSten Madsbad
Aug 15, 2017·Hospital Pharmacy·Danial E Baker
Apr 11, 2018·Diabetology & Metabolic Syndrome·Rodrigo Oliveira MoreiraRaquel C Lopes Assis Coelho
Feb 22, 2017·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Daniela Sofra
Mar 14, 2020·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Lawrence BlondeDenis Raccah
Jan 6, 2019·Advances in Therapy·Leigh PerreaultEric Johnson
Oct 14, 2021·Expert Opinion on Drug Safety·Peter Novodvorský, Martin Haluzík

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT01336023
NCT01392573

Software Mentioned

IDegLira
IDeg

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.